Understand the source comparison
LL-37 vs VIP: Which Peptide Works Better for Research?
LL-37 and VIP (vasoactive intestinal peptide) represent two of the most studied endogenous peptides in human biology. But they operate in completely different domains. LL-37, the only human cathelicidin, functions as a first-line antimicrobial defense peptide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- LL-37 and VIP (vasoactive intestinal peptide) represent two of the most studied endogenous peptides in human biology. But they operate in completely different domains. LL-37, the only human cathelicidin, functions as a first-line antimicrobial defense peptide expressed at epithelial surfaces. VIP, a 28-amino acid neuropeptide, acts as a systemic immune modulator and neurotransmitter across the gut-brain axis. Research published in Nature Immunology (2024) demonstrated that LL-37 directly disrupts bacterial membranes through electrostatic interaction, while VIP binds VPAC receptors to suppress pro-inflammatory cytokine cascades. Mechanisms so fundamentally distinct that comparing them as 'better or worse' misses the point entirely.
- Our team has worked with both peptides across immune modulation studies, wound healing protocols, and neuroprotection experiments. The question researchers ask isn't which peptide is superior. It's which peptide matches the biological pathway being investigated.
- What is the functional difference between LL-37 and VIP in research applications?
- LL-37 functions as a cationic antimicrobial peptide that directly disrupts microbial membranes and recruits immune cells to sites of infection, while VIP acts as an anti-inflammatory neuropeptide that downregulates cytokine production and promotes tissue repair through VPAC1 and VPAC2 receptor signaling. LL-37 is most relevant for studies involving innate immunity, wound healing, and pathogen response, whereas VIP is used in autoimmune disease models, neuroprotection research, and inflammatory bowel disease studies. The two peptides don't overlap in mechanism. They complement each other in multi-pathway experimental designs.